Details of the Drug-Related molecule(s) Interaction Atlas

BRL 37344 Drug Info

UNII-42FZ27IZLV; Brl-37344; 42FZ27IZLV; CHEMBL284782; BRL 37344; 2-(4-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)acetic acid; SB-206606; BRL37344; SB 206606; 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid; BRL-44092; GTPL567; 116049-78-6; SCHEMBL304308; CHEBI:131180; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-; ZINC3871771; BDBM50002133; Acetic acid, 2-(4-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-

Cross-matching ID

PubChem CID

9841972

ChEBI ID

CHEBI:131180

CAS Number

CAS 116049-78-6

TTD Drug ID

DMS4320

General Information of Drug (ID: DMS4320)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[2]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[3]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[4]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[5]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[6]
Rimiterol	DMA47C6	Asthma	CA23	Approved	[7]
Bitolterol	DMK6XAV	Chronic obstructive pulmonary disease	CA22	Approved	[8]
Nipradilol	DMA65ER	Angina pectoris	BA40	Approved	[9]
Vibegron	DMFR201	Overactive bladder	GC50.0	Approved	[10]
ONO-2506	DMCA2PJ	Stroke	8B20	Phase 2/3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34.
2	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
4	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
5	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
6	Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
7	Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
8	Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
9	Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
11	FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.